Exercise

Vasculitis and exercise

Why the exercise research in vasculitis is one small trial, what gets borrowed from other diseases to fill the blank, and how steroids change the question.
Quick answerThe direct evidence is one trial in Takayasu arteritis, where the disease activity score fell in the exercise group and the summary gives no figure for how far. One document does apply to you, and that is the 2017 American College of Rheumatology steroid guideline, which covers every adult on a long steroid course. That takes in most people here, and it calls for weight-bearing and strength-building work.
Nearly everything written about exercise and vasculitis is borrowed from other diseases, and that is hardly ever said out loud. The 2018 EULAR exercise advice covers inflammatory arthritis and osteoarthritis. Vasculitis is not one of those, and the 2017 steroid guideline does cover you, because it covers anyone on a long steroid course, whatever put them there. So those are two kinds of evidence answering two different questions. One is about your bones and the other is about your vasculitis, and running them together is how a page ends up claiming more than anybody has shown.

What the research found.

  • One randomized trial tested weight training in 342 patients with active Takayasu arteritis, twice a week for twelve weeks, and it is the only exercise trial in any vasculitis we could verify for this site. Its summary reports the disease activity score falling through the trial in the exercise group and barely changing in the control group. It gives no effect size, no confidence interval, and no P value for that, so the direction is known and the size is not.

    Li and colleagues, Clinical Cardiology, 2020

  • The 2017 American College of Rheumatology guideline covers every adult on a long steroid course. It strongly advises four things, which are getting your calcium and vitamin D right, doing weight-bearing and strength-building exercise, stopping smoking, and cutting back on alcohol. The guideline gives that advice at every age.

    Buckley and colleagues, Arthritis and Rheumatology, 2017

  • The 2018 EULAR activity advice judged the general public activity targets fit for two named disease groups, and vasculitis is not among them. Those two groups are inflammatory arthritis and osteoarthritis. The task force that wrote the advice was not considering vasculitis, so applying it here is a judgment call.

    Rausch Osthoff and colleagues, Annals of the Rheumatic Diseases, 2018

  • One study measured bone density in 198 patients with polymyalgia rheumatica, giant cell arteritis, or other kinds of vasculitis. Their steroid dose did not correlate with their bone density, and neither the current dose nor the total over time did. Three other things did correlate with it instead. Those were being lighter, having broken a bone in the spine before, and taking a heartburn drug, the kind doctors call a proton-pump inhibitor.

    Palmowski and colleagues, Cells, 2022

The movements, and how little is known about them here.

Almost nothing on this page has been tested in vasculitis, and the tool says which parts have at every tier rather than once at the bottom. One randomized trial of resistance exercise exists, in Takayasu arteritis, and it reports no figure anybody can quote. Everything else is extrapolated from the steroid guideline and from the much larger rheumatoid arthritis literature, dosed conservatively and labelled as extrapolation.

One randomized controlled trial has tested resistance exercise in a vasculitis. It enrolled 342 patients with active Takayasu arteritis diagnosed on magnetic resonance imaging, and randomized them to resistance exercise or to a relaxation control, twice a week for twelve weeks. The Birmingham Vascular Activity Score fell through the trial in the exercise group and was largely unchanged in the control group, while tumor necrosis factor alpha, C-reactive protein, and the sedimentation rate followed the same direction.

Two things stop that being the answer to your question. Its summary reports no effect size, no confidence interval, and no P value for any of it, so the direction of the change is known and the size of it is not. A trial of 342 patients in a disease this rare is also unusually large, which is a reason to read the full paper before anybody builds a program on it.

The properly sourced reason for training is a document about steroids rather than about vasculitis. The 2017 American College of Rheumatology guideline covers every adult starting or continuing a long steroid course, whatever put them there, and it strongly advises weight-bearing and strength-building exercise alongside calcium, vitamin D, stopping smoking, and drinking less. Most people with this diagnosis are in that position, so that guidance reaches them squarely even though it was written about their bones rather than their vessels.

Bodyweight only, and the first step is your rheumatologist confirming your disease is settled enough to train. Long steroid courses in induction treatment take muscle, and this tier is the direct counter to that, which is the one thing here with a guideline behind it. Build the five patterns here until you could repeat the session next week without dreading it.

Progress here once the bodyweight work is comfortable and your disease is confirmed settled. Working out your load takes one honest test: if the heaviest single squat you can manage with good form is fifty pounds, your working weight is thirty to thirty-five pounds. Start at the bottom of that range and retest every six to eight weeks.

Where the evidence doesn't exist

This intensity has not been tested in any vasculitis. It matches the majority of the rheumatoid arthritis resistance trials, including the two-year trial that used 50 to 70 percent of repetition maximum twice weekly. Conservative progression counts for more here than it does there, because there the checking has been done and here it hasn't.

This tier is the least defensible thing on the site and it is here because somebody will otherwise go looking for it elsewhere. Read the note below in full before you decide anything about it. If you take it to your rheumatologist and they say no, that is the right outcome rather than a disappointing one.

Where the evidence doesn't exist

This intensity has no supporting data in any vasculitis at all. In rheumatoid arthritis it rests on trials that describe their training only as high-intensity and give no percentage, and on a third trial that can't be found at all. Fragile vessels change the calculation completely, most of all where the aorta is involved, so do not attempt this tier without explicit clearance from your rheumatologist and ideally recent imaging confirming things are stable.

There is no aerobic exercise evidence in vasculitis that this site can cite. An earlier build of this guide rested the whole tab on a 2025 systematic review covering three studies in large vessel disease. That review is not in our source file and could not be found in any search, so it is not quoted here and nothing has been put in its place.

Walking remains the most sensible starting point on general grounds, and general grounds is all this is. It asks little of the joints, it needs no equipment, and its intensity is easy to judge by whether you can still talk. That isn't a vasculitis finding, and this tab is extrapolation from beginning to end.

Where the evidence doesn't exist

No interval training trial exists in any form of vasculitis, and this page doesn't fill that in by extrapolating. Heart involvement is a real feature of eosinophilic granulomatosis with polyangiitis, and fragile vessels are the defining problem of large vessel disease. So there is nothing on this tier, and there will not be until your rheumatologist has cleared it specifically, at which point it is their individual judgment rather than a protocol.

No movement break trial exists in vasculitis either, so this tab borrows its reasoning from elsewhere. One study measured seven days of movement in sixty-one patients with rheumatoid arthritis and found that sedentary time, and stretches of twenty minutes or longer, both correlated with a higher ten-year cardiovascular risk score. Both associations held whatever the person's moderate to vigorous activity added up to.

The reason to act on that here is the steroids rather than the vasculitis. Long courses take muscle and add weight, and fatigue from the disease keeps people in a chair for most of the day. These breaks are the cheapest available counter to both of those, and they cost you ninety seconds.

What exists, and what doesn't

The exercise research in vasculitis is very nearly empty, and saying so is the point of this page. One randomized trial tested weight training in 342 patients with active Takayasu arteritis, twice a week for twelve weeks, and it is the only exercise trial in any vasculitis we could verify for this site. Its summary reports the disease activity score falling through the trial in the group that trained, while it barely moved in the group doing relaxation instead. It gives no effect size, no confidence interval, and no P value anywhere, so what is known is the direction of the change rather than the size of it.

That blank is worth stating plainly. Each kind of vasculitis is rare on its own, so finding enough people for a trial is genuinely hard. The research money goes to treatment rather than to getting people moving again, which is why the advice on diagnosis and treatment is thinner here too.

Here is what usually happens on a page like this one. Evidence from other diseases gets used without anybody saying so, and exercise trials in rheumatoid arthritis get quoted alongside general population activity targets. They get quoted as though they covered vasculitis, and they may well apply, though that has never been shown.

The evidence that does apply

One guideline covers people with vasculitis squarely, and it is not about vasculitis at all. Most people with this diagnosis take steroids, often for a long stretch of time, and the 2017 American College of Rheumatology guideline on steroid-related bone loss covers everyone in that position. That is an odd route to being relevant, and it is also a sound one.

The guideline covers every adult starting or staying on a long steroid course, and gives strong advice at every age. Get your calcium and vitamin D right, do weight-bearing and strength-building exercise, stop smoking, and drink less. It then splits people by risk, so adults at low risk of a break should get calcium and vitamin D, while adults at middle or high risk should get a bone drug alongside those. A pill called a bisphosphonate is the first pick.

So there is a properly sourced reason for weight-bearing work and weight training in vasculitis. What that reason is about is your bones rather than your vasculitis, and the difference is worth keeping in view. The two questions come with very different amounts of evidence behind them.

Say one person tells you exercise lowers your vasculitis activity, and that claim rests on one trial reporting a direction and no number. Say another tells you it guards your bones on a steroid course, and that one has a guideline behind it. Those two sentences sound alike and are not.

What gets borrowed, and from where

The 2018 EULAR activity advice judged the general public targets fit for two disease groups. Those are inflammatory arthritis and osteoarthritis, and vasculitis is neither one of them. The task force was not writing about vasculitis, and the advice still gets quoted in this setting all the time.

It may transfer reasonably well, and here is the case for thinking so. Take a patient with well-controlled granulomatosis with polyangiitis and no organ damage, who is not obviously in a different position from a patient with well-controlled rheumatoid arthritis. That is an argument from what seems likely rather than from evidence, and it is worth knowing which of the two you are being handed.

Where it clearly does not transfer is large vessel disease. Takayasu arteritis and giant cell arteritis involve the aorta and its main branches, so blood pressure comes into it, along with vessels that have grown tight and arteries that have ballooned. Not one of those has any counterpart in inflammatory arthritis, so they are questions for the team looking after you.

Bone, which is where the real numbers are

The bone evidence in these patients is better than the exercise evidence, and it points somewhere unexpected. One study measured 198 patients at a single point in time, of whom 36 percent had polymyalgia rheumatica and 26 percent had giant cell arteritis. Another 17 percent of them had granulomatosis with polyangiitis. Their steroid dose did not correlate with their bone density, and neither the current dose nor the total over time did. That is the opposite of what nearly everybody expects.

Three other things did correlate with lower density, and the steroid dose was not among them. Being lighter, having broken a bone in the spine before, and taking a heartburn drug. That is a surprising result and it is easy to read the wrong way round, so the design deserves stating plainly.

Those patients were already on treatment, and most of them were already on bone protection. They were measured at one moment rather than followed, so the study cannot show what a trial comparing steroid exposure against no exposure would show. A snapshot of treated patients answers a much narrower question than it looks like it does.

Here is the sensible reading of that study. Bone protection in these patients looks like it is doing its job, and other risk factors deserve attention alongside the steroid dose. It is not evidence that long steroid courses are safe for bone, and the authors of that study didn't say it was.

Questions patients ask.

What does the exercise evidence in vasculitis say?

Very little, and that is the honest answer rather than a dodge. One randomized trial tested weight training in 342 patients with active Takayasu arteritis, and the disease activity score fell in the exercise group while barely moving in the control group. Its summary gives no effect size and no P value for that, so how much difference the training made can't be read from it. A trial that size in a disease this rare is also unusual enough to be worth reading in full before anyone builds a program on it.

Should I exercise while I'm on prednisone?

The steroid guideline answers this better than any vasculitis paper does. The 2017 American College of Rheumatology guideline covers every adult starting or staying on a long steroid course, whatever put them there. It strongly advises four things, which are getting your calcium and vitamin D right, doing weight-bearing and strength-building exercise, stopping smoking, and cutting back on alcohol. So it takes in most people with vasculitis.

Is exercise safe if my vessels are inflamed?

No trial in vasculitis is big enough to answer that with confidence, and nothing in what exists points to harm. The kinds of vasculitis differ hugely, with some staying in the skin while others involve the aorta, the main artery of the body. What is sensible in one may be wrong in another. So this is a question for the team looking after you rather than for a website, and that goes double if your large vessels or your heart are involved.

Why is there so little research?

Each kind of vasculitis is rare on its own, so finding enough people for an exercise trial is hard. The research money goes to treatment rather than to getting people moving again. That is why the advice here is thinner than it is for the commoner rheumatic diseases, which get more of it. It is how rare disease research works, and it is not a verdict on whether exercise is worth doing.

So what kind of exercise, then?

The only sourced answer is the steroid one, and it points at weight-bearing and strength-building work. That is what guards bone on a long steroid course. Past that, no prescription written for vasculitis exists in the research, and this page is not going to invent one. So say a trainer hands you a plan for vasculitis at this frequency, this length, and this intensity, and ask which study it came from.

Do steroids always damage my bones?

It is less simple than people make out, and one study is the reason to say so. It measured bone density in 198 patients with polymyalgia rheumatica, giant cell arteritis, or other vasculitis, and neither their current steroid dose nor their total correlated with it. Three other things did, which were being lighter, having broken a bone in the spine before, and taking a heartburn drug. Those patients were already on bone protection and were measured at one moment, so it argues for bone protection rather than against it.

References.

  1. Li G; Liu F; Wang Y et al. Effects of resistance exercise on treatment outcome and laboratory parameters of Takayasu arteritis with magnetic resonance imaging diagnosis: A randomized parallel controlled clinical trial. Clinical Cardiology. 2020;43:1273-1278. 10.1002/clc.23439Randomised parallel controlled clinical trial
  2. Buckley L; Guyatt G; Fink H et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis. Arthritis & Rheumatology. 2017;69:1521-1537. 10.1002/art.40137GRADE-based clinical practice guideline
  3. Rausch Osthoff A; Niedermann K; Braun J et al. 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. Annals of the Rheumatic Diseases. 2018;77:1251-1260. 10.1136/annrheumdis-2018-213585EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis
  4. Palmowski A; Wiebe E; Muche B et al. Glucocorticoids Are Not Associated with Bone Mineral Density in Patients with Polymyalgia Rheumatica, Giant Cell Arteritis and Other Vasculitides—Cross-Sectional Baseline Analysis of the Prospective Rh-GIOP Cohort. Cells. 2022;11:536. 10.3390/cells11030536Cross-sectional baseline analysis of a prospective cohort
  5. Fenton SAM; Veldhuijzen van Zanten JJCS; Kitas GD et al. Sedentary behaviour is associated with increased long-term cardiovascular risk in patients with rheumatoid arthritis independently of moderate-to-vigorous physical activity. BMC musculoskeletal disorders. 2018;18:131. 10.1186/s12891-017-1473-9Cross-sectional analysis of baseline data from 61 patients in the Physical Activity in Rheumatoid Arthritis study

This page gathers the published research on this subject into one place. The studies behind it were published between 1989 and 2026, and every figure links to the paper it came from. Those studies were peer reviewed. This summary of them was not. Dr. Sarah Luebker is reviewing these pages one at a time and has not reached this one yet, so it carries no medical review date and nothing here is her opinion or her advice to you. Each page gets updated as she reaches it. It is here in the meantime because the science is worth having in one organized place that is easy to find and easy to read. Talk to your own clinician before acting on any of it.